Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 1075-1079

  Azuma, Koji ^a   Nakashiro, Koh ichi ^a,b   Sasaki, Toyokazu ^a   Goda, Hiroyuki ^a   Onodera, Jun ^c   Tanji, Nozomu ^a,b   Yokoyama, Masayoshi ^a   Hamakawa, Hiroyuki ^a,b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c Koken Co Ltd   (Japan)

Author keywords

Androgen receptor; Atelocollagen; Prostate cancer; RNA interference

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ATELOCOLLAGEN; ATELOGENE; INTERFERON; MUTANT PROTEIN; SMALL INTERFERING RNA; SMALL INTERFERING RNA ATELOCOLLAGEN COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER GROWTH; CASTRATED MALE; CELL PROLIFERATION; CELL STRAIN 22RV1; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; XENOGRAFT;

ANDROGENS; BASE SEQUENCE; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING;

MUS MUSCULUS;

EID: 72949099673     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.024     Document Type: Article

References (25)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 59 2009 (2009) 225-249
2. Kozlowski J.M., Ellis W.J., and Grayhack J.T. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol. Clin. North Am. 18 (1991) 15-24
3. Martel C.L., Gumerlock P.H., Meyers F.J., and Lara P.N. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat. Rev. 29 (2003) 171-187
4. So A., Gleave M., Hurtado-Col A., and Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 23 (2005) 1-9
5. Linja M.J., Savinainen K.J., Saramäki O.R., Tammela T.L., Vessella R.L., and Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61 (2001) 3550-3555
6. Isaacs J.T., and Isaacs W.B. Androgen receptor outwits prostate cancer drugs. Nat. Med. 10 (2004) 26-27
7. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
8. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
9. Hankey B.F., Feuer E.J., Clegg L.X., Hayes R.B., Legler J.M., Prorok P.C., Ries L.A., Merrill R.M., and Kaplan R.S. Cancer surveillance series: interpreting trends in prostate cancer - part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J. Natl. Cancer Inst. 91 (1999) 1017-1024
10. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 28 (2001) 555-565
11. Potters L., Klein E.A., Kattan M.W., Reddy C.A., Ciezki J.P., Reuther A.M., and Kupelian P.A. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother. Oncol. 71 (2004) 29-33
12. Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., von Eschenbach A.C., Kuban D.A., and Rosen I. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 1097-1105
13. Scott W.W., Menon M., and Walsh P.C. Hormonal therapy of prostatic cancer. Cancer 45 (1980) 1929-1936
14. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group, Br. J. Urol. 79 (1997) 235-246.
15. Gregory C.W., Johnson Jr. R.T., Mohler J.L., French F.S., and Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61 (2001) 2892-2898
16. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., and Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (2004) 33-39
17. Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A., Ettinger S.L., Gleave M.E., and Nelson C.C. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68 (2008) 6407-6415
18. Hara S., Nakashiro K., Goda H., and Hamakawa H. Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem. Biophys. Res. Commun. 370 (2008) 123-128
19. Ochiya T., Takahama Y., Nagahara S., Sumita Y., Hisada A., Itoh H., Nagai Y., and Terada M. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat. Med. 5 (1999) 707-710
20. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., Kato T., Terada M., and Ochiya T. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32 (2004) e109
21. Takeshita F., Minakuchi Y., Nagahara S., Honma K., Sasaki H., Hirai K., Teratani T., Namatame N., Yamamoto Y., Hanai K., Kato T., Sano A., and Ochiya T. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA 102 (2005) 12177-12182
22. Wang B.E., Wang X.D., Emst J.A., Polakis P., and Gao W.Q. Regulation of epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt signaling. PLoS One 3 (2008) e2186
23. Valdman A., Fang X., Pang S.T., Ekman P., and Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60 (2004) 367-371
24. Zemskova M., Sahakian E., Bashkirova S., and Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 283 (2008) 20635-20644
25. Olabisi O.O., Mahon G.M., Kostenko E.V., Liu Z., Ozer H.L., and Whitehead I.P. Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res. 66 (2006) 6250-6257